Status:
UNKNOWN
Antenatal Allopurinol in Intrauterine Growth Restriction
Lead Sponsor:
UMC Utrecht
Conditions:
Fetal Growth Retardation
Eligibility:
All Genders
Phase:
NA
Brief Summary
Growth retardation in utero may be caused by uteroplacental vascular insufficiency. When Doppler ultrasound studies of the umbilical artery are abnormal pathological intrauterine growth restriction (I...
Eligibility Criteria
Inclusion
- Mothers with a gestational age (GA) of 30 to 36 weeks with:
- Foetal growth retardation (growth \<10th percentile) and
- Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)\>95th percentile)
Exclusion
- Congenital, chromosomal or syndromal abnormalities
- Positive screening for intrauterine viral infections
- Mothers with gout and high uric acid
- creatinine \> 100 umol/l
- ASAT \> 80 U/l, ALAT \> 80 U/l
- Uric acid \> 0,50 mmol/l
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00346463
Start Date
July 1 2006
End Date
July 1 2013
Last Update
April 28 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wilhelmina Children's Hospital / UMC Utrecht
Utrecht, Utrecht, Netherlands, 3508 AB